Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4350MR)

This product GTTS-WQ4350MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4350MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10787MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ9608MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ13367MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ9291MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ11636MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ6083MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ15095MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ4737MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BOS161721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW